Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
60.98-1.26 (-2.02%)
At close: 4:00 PM EDT

60.80 -0.18 (-0.30%)
After hours: 5:14 PM EDT

People also watch:
ACADCLVSCLDXPTCTICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open62.24
Prev Close62.24
Bid60.98 x 100
Ask61.80 x 100
Day's Range60.12 - 63.10
52wk Range8.00 - 63.73
1y Target EstN/A
Market Cap2.92B
P/E Ratio (ttm)-11.39
Beta1.71
Volume3,325,449
Avg Vol (3m)4,071,681
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.5 hours ago

    Catabasis Skyrockets on Sarepta Partnership

    Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.

  • American City Business Journals6 hours ago

    Sarepta announces Duchenne research partnership with Cambridge's Catabasis

    Sarepta Therapeutics on Thursday morning announced a research partnership with another Cambridge biotech focused on Duchenne muscular dystrophy, which CEO Ed Kaye said may be the first of several such deals. Fresh off the U.S. approval of its drug, Exondys51, Sarepta (SRPT) officials said the company plans to test that drug in combination with an anti-inflammatory drug being developed at Catabasis Pharmaceuticals (CATB) in mice. While no financial details of the collaboration were released, Kaye said they want to see if the two drugs together work better to help slow the damage to muscles.

  • Motley Fool7 hours ago

    One Biotech Crashes, the Other Skyrockets -- Here's Why

    Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.